60 related articles for article (PubMed ID: 31396953)
1. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.
Galaine J; Turco C; Vauchy C; Royer B; Mercier-Letondal P; Queiroz L; Loyon R; Mouget V; Boidot R; Laheurte C; Lakkis Z; Jary M; Adotévi O; Borg C; Godet Y
Int J Cancer; 2019 Dec; 145(11):3112-3125. PubMed ID: 31396953
[TBL] [Abstract][Full Text] [Related]
2. NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer.
Gnjatic S; Cao Y; Reichelt U; Yekebas EF; Nölker C; Marx AH; Erbersdobler A; Nishikawa H; Hildebrandt Y; Bartels K; Horn C; Stahl T; Gout I; Filonenko V; Ling KL; Cerundolo V; Luetkens T; Ritter G; Friedrichs K; Leuwer R; Hegewisch-Becker S; Izbicki JR; Bokemeyer C; Old LJ; Atanackovic D
Int J Cancer; 2010 Jul; 127(2):381-93. PubMed ID: 19937794
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the RBMS1/PRNP axis improves ferroptosis resistance-mediated oxaliplatin chemoresistance in colorectal cancer.
Xu Y; Hao J; Chen Q; Qin Y; Qin H; Ren S; Sun C; Zhu Y; Shao B; Zhang J; Wang H
Mol Carcinog; 2024 Feb; 63(2):224-237. PubMed ID: 37861356
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors.
Bezu L; Kepp O; Kroemer G
Oncoimmunology; 2023; 12(1):2272352. PubMed ID: 38126035
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Relationship Study of (
Wang S; Ge Q; Cong H; Zhang W; Liu H; Qu Z; Chen H; Zhuang C
ACS Pharmacol Transl Sci; 2024 May; 7(5):1386-1394. PubMed ID: 38751617
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
Ohara M; Ohara K; Kumai T; Ohkuri T; Nagato T; Hirata-Nozaki Y; Kosaka A; Nagata M; Hayashi R; Harabuchi S; Yajima Y; Oikawa K; Harabuchi Y; Sumi Y; Furukawa H; Kobayashi H
Cancer Immunol Immunother; 2020 Jun; 69(6):989-999. PubMed ID: 32086539
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy augments oxaliplatin-induced immunogenic cell death in colorectal cancer.
Wang X; Ren L; Ye L; Cao J
Cent Eur J Immunol; 2023; 48(3):189-202. PubMed ID: 37901869
[TBL] [Abstract][Full Text] [Related]
8. Alteration of chromatin high-order conformation associated with oxaliplatin resistance acquisition in colorectal cancer cells.
Li P; Shang X; Jiao Q; Mi Q; Zhu M; Ren Y; Li J; Li L; Liu J; Wang C; Shi Y; Wang Y; Du L
Exploration (Beijing); 2023 Aug; 3(4):20220136. PubMed ID: 37933235
[TBL] [Abstract][Full Text] [Related]
9. Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer.
Kalanxhi E; Meltzer S; Ree AH
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781554
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral bacteria generate a new class of therapeutically relevant tumor antigens in melanoma.
Sepich-Poore GD; Carter H; Knight R
Cancer Cell; 2021 May; 39(5):601-603. PubMed ID: 33974857
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunometabolism: advent, challenges, and perspective.
Dang Q; Li B; Jin B; Ye Z; Lou X; Wang T; Wang Y; Pan X; Hu Q; Li Z; Ji S; Zhou C; Yu X; Qin Y; Xu X
Mol Cancer; 2024 Apr; 23(1):72. PubMed ID: 38581001
[TBL] [Abstract][Full Text] [Related]
12. Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications.
Ge S; Zhao Y; Liang J; He Z; Li K; Zhang G; Hua B; Zheng H; Guo Q; Qi R; Shi Z
Cancer Cell Int; 2024 Mar; 24(1):105. PubMed ID: 38475858
[TBL] [Abstract][Full Text] [Related]
13. Role of T cells in cancer immunotherapy: Opportunities and challenges.
Ahmed H; Mahmud AR; Siddiquee MF; Shahriar A; Biswas P; Shimul MEK; Ahmed SZ; Ema TI; Rahman N; Khan MA; Mizan MFR; Emran TB
Cancer Pathog Ther; 2023 Apr; 1(2):116-126. PubMed ID: 38328405
[TBL] [Abstract][Full Text] [Related]
14. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
Matteucci L; Bittoni A; Gallo G; Ridolfi L; Passardi A
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958363
[TBL] [Abstract][Full Text] [Related]
15. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Thibaudin M; Fumet JD; Chibaudel B; Bennouna J; Borg C; Martin-Babau J; Cohen R; Fonck M; Taieb J; Limagne E; Blanc J; Ballot E; Hampe L; Bon M; Daumoine S; Peroz M; Mananet H; Derangère V; Boidot R; Michaud HA; Laheurte C; Adotevi O; Bertaut A; Truntzer C; Ghiringhelli F
Nat Med; 2023 Aug; 29(8):2087-2098. PubMed ID: 37563240
[TBL] [Abstract][Full Text] [Related]
16. Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J; Laureano RS; Vanmeerbeek I; Govaerts J; Naulaerts S; Borras DM; Kinget L; Fucíková J; Špíšek R; Jelínková LP; Kepp O; Kroemer G; Krysko DV; Coosemans A; Vaes RDW; De Ruysscher D; De Vleeschouwer S; Wauters E; Smits E; Tejpar S; Beuselinck B; Hatse S; Wildiers H; Clement PM; Vandenabeele P; Zitvogel L; Garg AD
Oncoimmunology; 2023; 12(1):2219591. PubMed ID: 37284695
[TBL] [Abstract][Full Text] [Related]
17. Subcellular Epithelial HMGB1 Expression Is Associated with Colorectal Neoplastic Progression, Male Sex, Mismatch Repair Protein Expression, Lymph Node Positivity, and an 'Immune Cold' Phenotype Associated with Poor Survival.
Porter RJ; Murray GI; Hapca S; Hay A; Craig SG; Humphries MP; James JA; Salto-Tellez M; Brice DP; Berry SH; McLean MH
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980751
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment.
Liu J; Yu Y; Liu C; Gao C; Zhuang J; Liu L; Wu Q; Ma W; Zhang Q; Sun C
Front Pharmacol; 2022; 13():1035954. PubMed ID: 36304169
[TBL] [Abstract][Full Text] [Related]
19. Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.
Peña-Romero AC; Orenes-Piñero E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406451
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic cell stress and death.
Kroemer G; Galassi C; Zitvogel L; Galluzzi L
Nat Immunol; 2022 Apr; 23(4):487-500. PubMed ID: 35145297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
